[(1R,2R,3R,4S,5S,8R,9R,10R)-9,10-diacetyloxy-4,5-dihydroxy-4-(hydroxymethyl)-8,12,15,15-tetramethyl-13-oxo-2-tricyclo[9.3.1.03,8]pentadec-11-enyl] acetate | 931421-94-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: [(1R,2R,3R,4S,5S,8R,9R,10R)-9,10-diacetyloxy-4,5-dihydroxy-4-(hydroxymethyl)-8,12,15,15-tetramethyl-13-oxo-2-tricyclo[9.3.1.03,8]pentadec-11-enyl] acetate
• CAS: 931421-94-2
• 化学式: C₂₆H₃₈O₁₀
• 分子量: 510.582
• InChiKey: UEYQHYBYFAVRJT-ZZNHCZCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  157
• 氢给体数：
  3
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  [(1R,2R,3R,4S,5S,8R,9R,10R)-9,10-diacetyloxy-4,5-dihydroxy-4-(hydroxymethyl)-8,12,15,15-tetramethyl-13-oxo-2-tricyclo[9.3.1.03,8]pentadec-11-enyl] acetate 在 吡啶 、 四丁基氟化铵 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 四氢呋喃 、 甲醇 、 甲苯 为溶剂， 生成 [(1R,2R,3R,4S,7R,10R,11R,12R,15R)-11,12-diacetyloxy-4,15-dihydroxy-10,14,17,17-tetramethyl-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] acetate
  参考文献：
  名称：

  Structure–activity relationships of some taxoids as multidrug resistance modulator

  摘要：

  1,7-Deoxy-4-deacetylbaccatin III (12) and its five analogues 6-9, 13, and their oxetane ring opened derivatives 14, 16, and 17, which were synthesized from taxinine, showed significant activity as MDR reversal agent by the assay of the calcein accumulation toward MDR human ovarian cancer 2780AD cells. The most effective compound 12 in this assay is actually efficient for the recovery of cytotoxic activity of paclitaxel (taxol), adriamycin (ADM), and vincristine (VCR) toward MDR 2780AD cells at the same level toward parental 2780 cells. This activity of 12 is very interesting because baccatin 111 (4) has no such MDR reversal activity but has cytotoxic activity. The essential functional groups inducing such a difference in biological activity between 4 and 12 are 4 alpha-acetoxyl for 4 and 4 alpha-hydroxyl for 12. In seven compounds possessing MDR reversal activity, compound 12 is the most desirable compound for anti-MDR cancer reversal agent, because it has the highest accumulation ability of anticancer agent in MDR cancer cells and weak cytotoxic activity. Compounds 8 and 13 showed significant cytotoxic activity toward HepG2 and VA-13, respectively, as well as MDR reversal activity. They are expected to become lead compounds for new types of anticancer agent or anti-MDR cancer agent. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.09.068
• 作为产物：
  描述：

  紫杉宁 在 四氧化锇 、 N-甲基吲哚酮 、 盐酸羟胺 作用下， 生成 [(1R,2R,3R,4S,5S,8R,9R,10R)-9,10-diacetyloxy-4,5-dihydroxy-4-(hydroxymethyl)-8,12,15,15-tetramethyl-13-oxo-2-tricyclo[9.3.1.03,8]pentadec-11-enyl] acetate
  参考文献：
  名称：

  Structure–activity relationships of some taxoids as multidrug resistance modulator

  摘要：

  1,7-Deoxy-4-deacetylbaccatin III (12) and its five analogues 6-9, 13, and their oxetane ring opened derivatives 14, 16, and 17, which were synthesized from taxinine, showed significant activity as MDR reversal agent by the assay of the calcein accumulation toward MDR human ovarian cancer 2780AD cells. The most effective compound 12 in this assay is actually efficient for the recovery of cytotoxic activity of paclitaxel (taxol), adriamycin (ADM), and vincristine (VCR) toward MDR 2780AD cells at the same level toward parental 2780 cells. This activity of 12 is very interesting because baccatin 111 (4) has no such MDR reversal activity but has cytotoxic activity. The essential functional groups inducing such a difference in biological activity between 4 and 12 are 4 alpha-acetoxyl for 4 and 4 alpha-hydroxyl for 12. In seven compounds possessing MDR reversal activity, compound 12 is the most desirable compound for anti-MDR cancer reversal agent, because it has the highest accumulation ability of anticancer agent in MDR cancer cells and weak cytotoxic activity. Compounds 8 and 13 showed significant cytotoxic activity toward HepG2 and VA-13, respectively, as well as MDR reversal activity. They are expected to become lead compounds for new types of anticancer agent or anti-MDR cancer agent. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.09.068